A New Breakthrough in Short Bowel Syndrome (SBS) Treatment!
For patients with Short Bowel Syndrome (SBS) and chronic intestinal failure (IF), long-term dependence on parenteral support (PS) can be challenging, leading to complications like sepsis, liver disease, and reduced quality of life. But a groundbreaking new treatment is changing the game!
A recent Phase 3 clinical trial published in Gastroenterology reveals that Glepaglutide, a long-acting GLP-2 analog, significantly reduces PS dependence and enhances intestinal function in SBS patients.
Key Findings: Â Significant Reduction in Parenteral Support â Glepaglutide TW resulted in a 26.6% greater reduction in PS volume compared to placebo. Â Improved Patient Outcomes â A higher percentage of Glepaglutide-treated patients reported feeling âmuch/very much improved.â Â Enhanced Intestinal Health â Patients saw a notable increase in citrulline levels, a key marker of intestinal function. Â Increased Enteral Autonomy â Some patients completely eliminated their need for PS after treatment.
 Why It Matters: Current SBS treatments focus on symptom management, but Glepaglutide offers a long-acting, effective approach to help patients regain independence from parenteral support while improving their overall quality of life.
 Want to dive deeper into this game-changing research?  Read the full article now and stay ahead in gastroenterology advancements! đ
 https://mdnewsline.com/glepaglutide-reduces-parenteral-support-in-short-bowel-syndrome/

















